## Drug of Choice for Active Trachoma **Key Point:** Azithromycin is the WHO-recommended first-line treatment for active trachoma caused by *Chlamydia trachomatis*. ### Mechanism and Rationale **High-Yield:** Azithromycin is a macrolide antibiotic that achieves high intracellular concentrations within epithelial cells, making it ideal for chlamydial infections which are obligate intracellular pathogens. It is given as a single oral dose (20 mg/kg) or as a 3-day course. ### Comparison of Trachoma Treatment Options | Drug | Route | Efficacy | Advantages | Disadvantages | |------|-------|---------|------------|---------------| | **Azithromycin** | Oral | >95% | Single dose, good tissue penetration, systemic effect | Cost in resource-limited settings | | Tetracycline ointment | Topical | 60–70% | Inexpensive, widely available | Requires 6-week course, poor compliance | | Ciprofloxacin | Topical | 70–80% | Broad spectrum | Less effective than macrolides for chlamydia | | Gentamicin | Topical | Poor | Gram-negative coverage | Ineffective against chlamydia | ### WHO Guidelines **Clinical Pearl:** The WHO "A" strategy (Antibiotics) recommends azithromycin as the preferred agent because: 1. Single-dose oral therapy improves compliance in resource-limited settings 2. Systemic absorption treats both ocular and nasopharyngeal carriage 3. Prevents reinfection and transmission within communities 4. Cost-effective at population scale **Mnemonic:** **SAFE Strategy** for trachoma elimination: - **S**urgery (for trichiasis) - **A**ntibiotics (azithromycin) - **F**acial cleanliness - **E**nvironmental improvement ### Clinical Context Tetracycline ointment was historically the standard but has been superseded by azithromycin due to superior compliance and efficacy. Topical agents alone cannot reliably treat nasopharyngeal chlamydial carriage, which perpetuates community transmission.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.